These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36773700)

  • 1. Prescribing Stimulants for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Co-occurring Cannabis Use: Considerations for Managing a Clinical Dilemma.
    Dernbach MR; Gray KM; Borich A; Seery E; Russo SB; Lewis ET; Gwynette MF
    J Am Acad Child Adolesc Psychiatry; 2023 Aug; 62(8):842-846. PubMed ID: 36773700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician perceptions of the use of medications for attention deficit hyperactivity disorder.
    Stockl KM; Hughes TE; Jarrar MA; Secnik K; Perwien AR
    J Manag Care Pharm; 2003; 9(5):416-23. PubMed ID: 14613439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
    Winhusen TM; Lewis DF; Riggs PD; Davies RD; Adler LA; Sonne S; Somoza EC
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):455-63. PubMed ID: 22040190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician.
    Upadhyaya HP
    Prim Care Companion J Clin Psychiatry; 2008; 10(3):211-21. PubMed ID: 18615170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
    Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
    Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician practices to prevent ADHD stimulant diversion and misuse.
    Colaneri N; Keim S; Adesman A
    J Subst Abuse Treat; 2017 Mar; 74():26-34. PubMed ID: 28132697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pearls, perils, and pitfalls in the assessment and treatment of attention-deficit/hyperactivity disorder in adolescents.
    Obioha O; Adesman A
    Curr Opin Pediatr; 2014 Feb; 26(1):119-29. PubMed ID: 24370490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.
    Martinez-Raga J; Ferreros A; Knecht C; de Alvaro R; Carabal E
    Ther Adv Drug Saf; 2017 Mar; 8(3):87-99. PubMed ID: 28382197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Cannabis, Cocaine and Alcohol Use Impact Differently on Adult Attention Deficit/Hyperactivity Disorder Clinical Picture?
    Spera V; Pallucchini A; Carli M; Maiello M; Maremmani AGI; Perugi G; Maremmani I
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33918432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Household Diversion of Prescription Stimulants: Medication Misuse by Parents of Children with Attention-Deficit/Hyperactivity Disorder.
    Pham T; Milanaik R; Kaplan A; Papaioannou H; Adesman A
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):741-746. PubMed ID: 28686059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adult attention deficit hyperactivity disorder symptom profiles and concurrent problems with alcohol and cannabis: sex differences in a representative, population survey.
    Kolla NJ; van der Maas M; Toplak ME; Erickson PG; Mann RE; Seeley J; Vingilis E
    BMC Psychiatry; 2016 Feb; 16():50. PubMed ID: 26920911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
    Wilens TE; Adler LA; Adams J; Sgambati S; Rotrosen J; Sawtelle R; Utzinger L; Fusillo S
    J Am Acad Child Adolesc Psychiatry; 2008 Jan; 47(1):21-31. PubMed ID: 18174822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
    Otasowie J; Castells X; Ehimare UP; Smith CH
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006997. PubMed ID: 25238582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician Training and Qualification to Educate Patients on Attention-Deficit/Hyperactivity Disorder Stimulant Diversion and Misuse.
    Colaneri N; Keim SA; Adesman A
    J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):554-561. PubMed ID: 30124331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
    Ng QX
    J Child Adolesc Psychopharmacol; 2017 Mar; 27(2):112-116. PubMed ID: 27813651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
    Wigal SB
    CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.